Epigenetic regulation of signal transducer and activator of transcription 3 in acute myeloid leukemia

Leukemia Research

Volumn 32, Issue 7, 2008, Pages 1005-1014

 

^a Gupta), Sampa   (United States)

Author keywords

Acute myeloid leukemia; Hypermethylation; Signal transducer and activator of transcription 3

Indexed keywords

HISTONE DEACETYLASE; ONCOPROTEIN; PROTEIN SH2; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP 1; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ACUTE GRANULOCYTIC LEUKEMIA; CELL PROLIFERATION; DIMERIZATION; GENETIC TRANSCRIPTION; HUMAN; LIGAND BINDING; METHYLATION; NONHUMAN; OLIGOMERIZATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION;

EPIGENESIS, GENETIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; METHYLATION; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 41949110321     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.11.035     Document Type: Review

References (90)

1. Xia Z., Baer M.R., Block A.W., Baumann H., and Wetzler M. Expression of signal transducers and activators of transcription proteins in acute myeloid leukemia blasts. Cancer Res 58 (1998) 3173-3180
2. Benekli M., Xia Z., Donohue K.A., Ford L.A., Pixley L.A., Baer M.R., et al. Constitutive activity of signal transducer and activator of transcription 3 protein in acute myeloid leukemia blasts is associated with short disease-free survival. Blood 99 (2002) 252-257
3. Wetzler M., Brady M.T., Tracy E., Li Z.R., Donohue K.A., O'Loughlin K.L., et al. Arsenic trioxide affects signal transducer and activator of transcription proteins through alteration of protein tyrosine kinase phosphorylation. Clin Cancer Res 12 (2006) 6817-6825
4. Blanchard F., Tracy E., Smith J., et al. DNA methylation controls the responsiveness of hepatoma cells to leukemia inhibitory factor. Hepatology 38 (2003) 1516-1528
5. Benekli M., Baer M.R., Baumann H., and Wetzler M. Signal transducer and activator of transcription proteins in leukemias. Blood 101 (2003) 2940-2954
6. Wormald S., and Hilton D.J. Inhibitors of cytokine signal transduction. J Biol Chem 279 (2004) 821-824
7. Rakesh K., and Agrawal D.K. Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol 70 (2005) 649-657
8. Valentino L., and Pierre J. JAK/STAT signal transduction: regulators and implication in hematological malignancies. Biochem Pharmacol 71 (2006) 713-721
9. Khwaja A. The role of Janus kinases in haemopoiesis and haematological malignancy. Br J Haematol 134 (2006) 366-384
10. Minoo P., Zadeh M.M., Rottapel R., Lebrun J.J., and Ali S. A novel SHP-1/Grb2-dependent mechanism of negative regulation of cytokine-receptor signaling: contribution of SHP-1 C-terminal tyrosines in cytokine signaling. Blood 103 (2004) 1398-1407
11. Tanaka T., Soriano M.A., and Grusby M.J. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22 (2005) 729-736
12. Antequera F., and Bird A. Number of CpG islands and genes in human and mouse. Proc Natl Acad Sci USA 90 (1993) 11995-11999
13. Gardiner-Garden M., and Frommer M. CpG islands in vertebrate genomes. J Mol Biol 196 (1987) 261-282
14. Takai D., and Jones P.A. Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99 (2002) 3740-3745
15. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
16. Baylin S.B., Herman J.G., Graff J.R., Vertino P.M., and Issa J.P. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 72 (1998) 141-196
17. Freitag M., and Selker E.U. Controlling DNA methylation: many roads to one modification. Curr Opin Genet Dev 15 (2005) 191-199
18. Klose R.J., and Bird A.P. Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31 (2006) 89-97
19. Jeltsch A., Nellen W., and Lyko F. Two substrates are better than one: dual specificities for Dnmt2 methyltransferases. Trends Biochem Sci 31 (2006) 306-308
20. Clevenger C.V. Roles and regulation of stat family transcription factors in human breast cancer. Am J Pathol 165 (2004) 1449-1460
21. Chen H., Ye D., Xie X., Chen B., and Lu W. VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 94 (2004) 630-635
22. Silver D.L., Naora H., Liu J., Cheng W., and Montell D.J. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 64 (2004) 3550-3558
23. Sanchez-Ceja S.G., Reyes-Maldonado E., Vazquez-Manriquez M.E., Lopez-Luna J.J., Belmont A., and Gutierrez-Castellanos S. Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer 54 (2006) 163-168
24. Toyonaga T., Nakano K., Nagano M., Zhao G., Yamaguchi K., Kuroki S., et al. Blockade of constitutively activated Janus kinase/signal transducer and activator of transcription-3 pathway inhibits growth of human pancreatic cancer. Cancer Lett 201 (2003) 107-116
25. Niwa Y., Kanda H., Shikauchi Y., Saiura A., Matsubara K., Kitaqawa T., et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 24 (2005) 6406-6417
26. Wu C., Sun M., Liu L., and Zhou G.W. The function of the protein tyrosine phosphatase SHP-1 in cancer. Gene 306 (2003) 1-12
27. Thangaraju M., Sharma K., Liu D., Shen S.H., and Srikant C.B. Interdependent regulation of intracellular acidification and SHP-1 in apoptosis. Cancer Res 59 (1999) 1649-1654
28. Mok S.C., Kwok T.T., Berkowitz R.S., Barrett A.J., and Tsui F.W. Overexpression of the protein tyrosine phosphatase, nonreceptor type 6 (PTPN6), in human epithelial ovarian cancer. Gynecol Oncol 57 (1995) 299-303
29. Calvisi D.F., Ladu S., Gorden A., Farina M., Conner E.A., Lee J.S., et al. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC. Gastroenterology 130 (2006) 1117-1128
30. Yoshikawa H., Matsubara K., Qian G.S., Jackson P., Groopman J.D., Manning J.E., et al. SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity. Nat Genet 28 (2001) 29-35
31. Nagai H., Naka T., Terada Y., Komazaki T., Yabe A., Jin E., et al. Hypermethylation associated with inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human hepatoblastomas. J Hum Genet 48 (2003) 65-69
32. Fukushima N., Sato N., Sahin F., Su G.H., Hruban R.H., and Goggins M. Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 89 (2003) 338-343
33. Komazaki T., Nagai H., Emi M., Terada Y., Yabe A., Jin E., et al. Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 34 (2004) 191-194
34. Oshimo Y., Kuraoka K., Nakayama H., Kitadai Y., Yoshida K., Chayama K., et al. Epigenetic inactivation of SOCS-1 by CpG island hypermethylation in human gastric carcinoma. Int J Cancer 112 (2004) 1003-1009
35. Fujitake S., Hibi K., Okochi O., Kodera Y., Ito K., Akiyama S., et al. Aberrant methylation of SOCS-1 was observed in younger colorectal cancer patients. J Gastroenterol 39 (2004) 120-124
36. Lin S.Y., Yeh K.T., Chen W.T., Chen H.C., Chen S.T., Chiou H.Y., et al. Promoter CpG methylation of tumor suppressor genes in colorectal cancer and its relationship to clinical features. Oncol Rep 11 (2004) 341-348
37. He B., You L., Uematsu K., Zang K., Xu Z., Lee A.Y., et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci USA 100 (2003) 14133-14138
38. Weber A., Hengge U.R., Bardenheuer W., Bardenheuer W., Tischoff I., Sommerer F., et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 24 (2005) 6699-6708
39. Liu B., and Shuai K. Induction of apoptosis by protein inhibitor of activated Stat1 through c-Jun NH2-terminal kinase activation. J Biol Chem 276 (2001) 36624-36631
40. Rycyzyn M.A., and Clevenger C.V. The intranuclear prolactin/cyclophilin B complex as a transcriptional inducer. Proc Natl Acad Sci USA 99 (2002) 6790-6795
41. Ogata Y., Osaki T., Naka T., Iwahori K., Furukawa M., Nagatomo I., et al. Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia 8 (2006) 817-825
42. Mitchell T.J., and John S. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology 114 (2005) 301-312
43. Weber-Nordt R.M., Egen C., Wehinger J., Ludwig W., Gouilleux-Gruart V., Mertelsmann R., et al. Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines. Blood 88 (1996) 809-816
44. De Vos J., Jourdan M., Tarte K., Jasmin C., and Klein B. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells. Br J Haematol 109 (2000) 823-828
45. Hirano T., Ishihara K., and Hibi M. Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors. Oncogene 19 (2000) 2548-2556
46. Zhang Q., Raghunath P.N., Vonderheid E., Odum N., and Wasik M.A. Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am J Pathol 157 (2000) 1137-1146
47. Zhang Q., Wang H.Y., Marzec M., Raghunath P.N., Nagasawa T., and Wasik M.A. STAT3- and DNA methyltransferase 1-mediated epigenetic silencing of SHP-1 tyrosine phosphatase tumor suppressor gene in malignant T lymphocytes. Proc Natl Acad Sci USA 102 (2005) 6948-6953
48. Chim C.S., Fung T.K., Cheung W.C., Liang R., and Kwong Y.L. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103 (2004) 4630-4635
49. Galm O., Yoshikawa H., Esteller M., Osieka R., and Herman J.G. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101 (2003) 2784-2788
50. Depil S., Saudemont A., and Quesnel B. SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia 17 (2003) 1678-1679
51. Kolonics A., Apati A., Nahajevszky S., Gati R., Brozik A., and Magocsi M. Unregulated activation of STAT-5, ERK1/2 and c-Fos may contribute to the phenotypic transformation from myelodysplastic syndrome to acute leukaemia. Haematologia (Budap) 31 (2001) 125-138
52. Kaminskas E., Farrell A., Abraham S., Baird A., Hsieh L.S., Lee S.L., et al. Approval summary: azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res 11 (2005) 3604-3608
53. Fenaux P. Inhibitors of DNA methylation: beyond myelodysplastic syndromes. Nat Clin Pract Oncol 2 Suppl. 1 (2005) S36-S44
54. Silverman L.R., Demakos E.P., Peterson B.L., Kornblith A.B., Holland J.C., Odchimar-Reissig R., et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20 (2002) 2429-2440
55. Kantarjian H., Issa J.P., Rosenfeld C.S., Bennett J.M., Albitar M., DiPersio J., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 (2006) 1794-1803
56. Daskalakis M., Nguyen T.T., Nguyen C., Guldberg P., Köhler G., Wijermans P., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100 (2002) 2957-2964
57. Kantarjian H., Oki Y., Garcia-Manero G., Huang X., O'Brien S., Cortes J., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 (2007) 52-57
58. Johan M.F., Bowen D.T., Frew M.E., Goodeve A.C., and Reilly J.T. Aberrant methylation of the negative regulators RASSFIA, SHP-1 and SOCS-1 in myelodysplastic syndromes and acute myeloid leukaemia. Br J Haematol 129 (2005) 60-65
59. Brakensiek K., Langer F., Schlegelberger B., Kreipe H., and Lehmann U. Hypermethylation of the suppressor of cytokine signalling-1 (SOCS-1) in myelodysplastic syndrome. Br J Haematol 130 (2005) 209-217
60. Ueda M., Ota J., Yamashita Y., Choi Y.L., Ohki R., Wada T., et al. DNA microarray analysis of stage progression mechanism in myelodysplastic syndrome. Br J Haematol 123 (2003) 288-296
61. Stirewalt D.L., Meshinchi S., and Radich J.P. Molecular targets in acute myelogenous leukemia. Blood Rev 17 (2003) 15-23
62. Choudhary C., Muller-Tidow C., Berdel W.E., and Serve H. Signal transduction of oncogenic Flt3. Int J Hematol 82 (2005) 93-99
63. Chim C.S., Wong A.S., and Kwong Y.L. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias. Ann Hematol 83 (2004) 527-532
64. Chen C.Y., Tsay W., Tang J.L., Shen H.L., Lin S.W., Huang S.Y., et al. SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia. Genes Chromosomes Cancer 37 (2003) 300-305
65. Watanabe D., Ezoe S., Fujimoto M., Kimura A., Saito Y., Nagai H., et al. Suppressor of cytokine signalling-1 gene silencing in acute myeloid leukaemia and human haematopoietic cell lines. Br J Haematol 126 (2004) 726-735
66. Gilliland D.G., and Griffin J.D. Role of FLT3 in leukemia. Curr Opin Hematol 9 (2002) 274-281
67. Lubbert M., and Minden M. Decitabine in acute myeloid leukemia. Semin Hematol 42 (2005) S38-S42
68. Yang A.S., Doshi K.D., Choi S.W., Mason J.B., Mannari R.K., Gharybian V., et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 66 (2006) 5495-5503
69. Garcia-Manero G., Kantarjian H.M., Sanchez-Gonzalez B., Yang H., Rosner G., Verstovsek S., et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 108 (2006) 3271-3279
70. Frantsve J., Schwaller J., Sternberg D.W., Kutok J., and Gilliland D.G. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 21 (2001) 3547-3557
71. Roman-Gomez J., Jimenez-Velasco A., Agirre X., Prosper F., Heiniger A., and Torres A. Lack of CpG island methylator phenotype defines a clinical subtype of T-cell acute lymphoblastic leukemia associated with good prognosis. J Clin Oncol 23 (2005) 7043-7049
72. de Groot R.P., Raaijmakers J.A.M., Lammers J-WJ, Jove R., and Koenderman L. STAT5 activation by BCR-Abl contributes to transformation of K562 leukemia cells. Blood 94 (1999) 1108-1112
73. Sillaber C., Gesbert F., Frank D.A., Sattler M., and Griffin J.D. STAT5 activation contributes to growth and viability in Bcr/Abl-transformed cells. Blood 95 (2000) 2118-2125
74. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., Cervantes F., Barrios M., Colomer D., et al. The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica 89 (2004) 42-48
75. Schultheis B., Carapeti-Marootian M., Hochhaus A., Weisser A., Goldman J.M., and Melo J.V. Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism. Blood 99 (2002) 1766-1775
76. Sakai I., Takeuchi K., Yamauchi H., Narumi H., and Fujita S. Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood 100 (2002) 2926-2931
77. Issa J.P., Gharibyan V., Cortes J., Jelinek J., Morris G., Verstovsek S., et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 23 (2005) 3948-3956
78. Sternberg D.W., Tomasson M.H., Carroll M., Curley D.P., Barker G., Caprio M., et al. The TEL/PDGFbeta R fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways. Blood 98 (2001) 3390-3397
79. Frank D.A., Mahajan S., and Ritz J. B lymphocytes from patients with chronic lymphocytic leukemia contain signal transducer and activator of transcription (STAT) 1 and STAT3 constitutively phosphorylated on serine residues. J Clin Invest 100 (1997) 3140-3148
80. Kossev P.M., Raghunath P.N., Bagg A., Schuster S., Tomaszewski J.E., and Wasik M.A. SHP-1 expression by malignant small B-cell lymphomas reflects the maturation stage of their normal B-cell counterparts. Am J Surg Pathol 25 (2001) 949-955
81. James C., Ugo V., Casadevall N., Constantinescu S.N., and Vainchenker W. A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med 11 (2005) 546-554
82. Bock O., Hussein K., Brakensiek K., Buhr T., Schlue J., Wiese B., et al. The suppressor of cytokine signalling-1 (SOCS-1) gene is overexpressed in Philadelphia chromosome negative chronic myeloproliferative disorders. Leuk Res 31 (2007) 799-803
83. Hookham M.B., Elliot J., Suessmuth Y., Staerk J., Ward A.C., Vainchenker W., et al. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109 (2007) 4924-4929
84. Aparicio A., Eads C.A., Leong L.A., Laird P.W., Newman E.M., Synolds T.W., et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 51 (2003) 231-239
85. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103 (2004) 1635-1640
86. Chan A.T., Tao Q., Robertson K.D., Flinn J.W., Mann R.B., Klencke B., et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol 22 (2004) 1373-1381
87. Samlowski W.E., Leachman S.A., Wade M., Cassidy P., Porter-Gill P., Busby K., et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 23 (2005) 3897-3905
88. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 12 (2006) 5777-5785
89. Calin G.A., and Croce C.M. MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene 25 (2006) 6202-6210
90. Krichevsky A.M., Sonntag K.C., Isacson O., and Kosik K.S. Specific microRNAs modulate embryonic stem cell-derived neurogenesis. Stem Cells 24 (2006) 857-864